AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 21 min read$GILD

O'Day Daniel Patrick sold $1.9M of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 15,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $126.29 ($126.09–$127.08, $1.89M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but the disclosure alone does not change Gilead’s fundamentals or near-term outlook based on the provided text.

02

Market read

Management selling under a 10b5-1 plan is typically low-signal for fundamentals, so the trading impact is likely modest.

03

What to watch

10b5-1 plans are pre-scheduled and often reduce the informational content of insider sales; the article provides no reason for the sale beyond the plan.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-02, covering sales executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction report for Gilead Sciences, filed after the CEO executed open-market sales under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead CEO O'Day sold about $1.89M of GILD shares via an open-market transaction under a pre-arranged 10b5-1 plan on 2026-07-01.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan and no accompanying operational or guidance change in the text.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large CEO sale can be interpreted by some traders as a confidence signal, even if executed under a 10b5-1 plan.

Key entities

  • issuer
    Gilead Sciences, Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    O'Day Daniel Patrick

    Chairman & CEO who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GILD insider trading history →

Related articles

OCT 16
$GILDMed

5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

pharmacytimes.com5 min
OCT 15
$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 9/10

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 8/10

Vir Biotechnology partners with Gilead on cancer therapies

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.

investing.com2 min